Iovance Biotherapeutics Shares Surge 33% Following Revenue Guidance Increase
Written with artificial intelligence.
Iovance Biotherapeutics, Inc. (IOVA) shares jumped 33% after the company raised its fiscal year 2026 revenue outlook to between $410 million and $420 million. This adjustment reflects strong U.S. demand for its products Amtagvi and Proleukin.
Stock Performance
Iovance Biotherapeutics, Inc. (IOVA) experienced a significant rise in its stock price, increasing by approximately 33% on Tuesday morning. The shares traded at $14.59 on the Nasdaq, up from an opening price of $12.79, reaching a high of $14.60 during the session. Over the past year, the stock has fluctuated between $1.76 and $14.60.
Revenue Guidance Update
The surge in stock price follows the company's announcement to raise its total revenue guidance for fiscal year 2026. Iovance now expects revenues to be in the range of $410 million to $420 million. This revised forecast represents an increase of $55 million, or about 15%, from the previous guidance of $350 million to $370 million, indicating an anticipated annual growth rate of nearly 60%.
Market Impact
The upward revision in revenue outlook is attributed to robust demand for Iovance's therapies, particularly Amtagvi and Proleukin, in the U.S. market. Investors are reacting positively to this news, reflecting confidence in the company's growth trajectory as it continues to expand its market presence.